128 related articles for article (PubMed ID: 37600745)
1. Edema of the face and extremities secondary to pemetrexed.
Doyle T; Fay CJ; Pisano C; LeBoeuf NR
JAAD Case Rep; 2023 Aug; 38():20-22. PubMed ID: 37600745
[No Abstract] [Full Text] [Related]
2. PEMETREXED-INDUCED PSEUDOCELLULITIS - A RARE CUTANEOUS ADVERSE REACTION TO MULTI-TARGETED ANTIFOLATE THERAPY.
Wollina U; Hansel G; Zschuppe E; Tchernev G
Georgian Med News; 2017 Jun; (267):81-84. PubMed ID: 28745612
[TBL] [Abstract][Full Text] [Related]
3. Pemetrexed-Induced Pseudocellulitis Reaction With Eosinophilic Infiltrate on Skin Biopsy.
Tracey EH; Modi B; Micheletti RG
Am J Dermatopathol; 2017 Jan; 39(1):e1-e2. PubMed ID: 27415636
[TBL] [Abstract][Full Text] [Related]
4. Skin toxicities compromise prolonged pemetrexed treatment.
Eguia B; Ruppert AM; Fillon J; Lavolé A; Gounant V; Epaud C; Milleron B; Moguelet P; Wislez M; Frances C; Cadranel J
J Thorac Oncol; 2011 Dec; 6(12):2083-9. PubMed ID: 21892100
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed-Induced Pseudocellulitis: A Diagnostic Conundrum.
Horton LA; Lyons AB; Kwa MC; Chaffins ML; Veenstra J
Cureus; 2024 Jan; 16(1):e52114. PubMed ID: 38344595
[TBL] [Abstract][Full Text] [Related]
6. Eyelid and feet edema induced by pemetrexed.
Kastalli S; Charfi O; Sahnoun R; Lakhoua G
Indian J Pharmacol; 2016; 48(6):741-742. PubMed ID: 28066120
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed-induced lower limb pseudocellulitis.
Liau MM; Santosa A; Huang J; Tan LC
Clin Exp Dermatol; 2017 Dec; 42(8):914-916. PubMed ID: 28815694
[No Abstract] [Full Text] [Related]
8. A case series of dose-limiting peripheral edema observed in patients treated with pemetrexed.
D'Angelo SP; Kris MG; Pietanza MC; Rizvi NA; Azzoli CG
J Thorac Oncol; 2011 Mar; 6(3):624-6. PubMed ID: 21317741
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma.
Bas O; Ozbek A; Guven D; Aktepe O; Kılıc L; Kertmen N; Erman M
J Oncol Pharm Pract; 2020 Jul; 26(5):1230-1233. PubMed ID: 31735133
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed-induced pseudocellulitis.
Lo Y; Wu WH
Kaohsiung J Med Sci; 2020 Nov; 36(11):953-954. PubMed ID: 32643863
[No Abstract] [Full Text] [Related]
11. Periorbital edema and erythema: an unusual localization of DLE in a patient with psoriasis.
Serarslan G; Atik E; Sarikaya G
J Dermatol; 2011 May; 38(5):486-8. PubMed ID: 21352328
[TBL] [Abstract][Full Text] [Related]
12. The effect of a mucopolysaccharide-cartilage complex healing ointment on Er:YAG laser resurfaced facial skin.
Tanzi EL; Perez M
Dermatol Surg; 2002 Apr; 28(4):305-8. PubMed ID: 11966786
[TBL] [Abstract][Full Text] [Related]
13. Case of remitting seronegative symmetrical synovitis with pitting edema (RS3PE syndrome) showing dermatomyositis-like eruption.
Takeda K; Fujita J; Fujii T; Tanabe H; Mochizuki T; Yanagihara M
J Dermatol; 2010 Jan; 37(1):102-6. PubMed ID: 20175831
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of Morbihan disease with total glucosides of paeony: A case report.
Zhou LF; Lu R
World J Clin Cases; 2022 Jul; 10(19):6688-6694. PubMed ID: 35979289
[TBL] [Abstract][Full Text] [Related]
15. Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189.
Garon EB; Aerts J; Kim JS; Muehlenbein CE; Peterson P; Rizzo MT; Gadgeel SM
Lung Cancer; 2021 May; 155():53-60. PubMed ID: 33730652
[TBL] [Abstract][Full Text] [Related]
16. Bilateral periorbital leukemia cutis presenting as suspected cellulitis.
Gupta L; Levoska MA; Sharma T; Honda K; Prendes MA
Orbit; 2022 Aug; 41(4):506-508. PubMed ID: 33682591
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Langer CJ; Gadgeel SM; Borghaei H; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Ge Y; Raftopoulos H; Gandhi L;
Lancet Oncol; 2016 Nov; 17(11):1497-1508. PubMed ID: 27745820
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study.
Horinouchi H; Nogami N; Saka H; Nishio M; Tokito T; Takahashi T; Kasahara K; Hattori Y; Ichihara E; Adachi N; Noguchi K; Souza F; Kurata T
Cancer Sci; 2021 Aug; 112(8):3255-3265. PubMed ID: 34036692
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.
Rodríguez-Abreu D; Powell SF; Hochmair MJ; Gadgeel S; Esteban E; Felip E; Speranza G; De Angelis F; Dómine M; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Kurata T; Yang J; Pietanza MC; Souza F; Garassino MC
Ann Oncol; 2021 Jul; 32(7):881-895. PubMed ID: 33894335
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
Garassino MC; Gadgeel S; Speranza G; Felip E; Esteban E; Dómine M; Hochmair MJ; Powell SF; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Kurata T; Gray JE; Schwarzenberger P; Jensen E; Pietanza MC; Rodríguez-Abreu D
J Clin Oncol; 2023 Apr; 41(11):1992-1998. PubMed ID: 36809080
[No Abstract] [Full Text] [Related]
[Next] [New Search]
